期刊文献+

标准化屋尘螨提取液治疗儿童支气管哮喘的安全性研究 被引量:5

Safety of specific immunotherapy with standardized house-dust mite vaccine in asthmatic children
原文传递
导出
摘要 目的通过观察进行标准化屋尘螨特异性免疫治疗(脱敏治疗)的支气管哮喘(简称哮喘)患儿,在脱敏治疗过程中出现的不良反应,评价脱敏治疗的安全性。方法对在苏州大学附属儿童医院哮喘专科门诊临床确诊的110例哮喘患儿,应用(丹麦ALK—Abello公司安脱达)标准化屋尘螨提取液进行皮下注射脱敏治疗。观察每次注射后不良反应发生情况,统计脱敏治疗的不良反应发生率。结果在110例患儿共接受免疫注射2332人次,发生局部不良反应291人次(发生率12.48%),其中速发型局部不良反应146人次(6.26%),迟发型局部不良反应145人次(6.22%)。局部不良反应在20~800SQU、2000~80oooSQU、100 000SQU阶段的发生率分别是:1.05%(6/569)、12.05%(97/805)和19.62%(188/958),差异有统计学意义。发生全身不良反应79人次(3.39%),1例次为3级非致命性全身反应,其余均为轻度全身反应(包括哮喘、过敏性鼻炎、过敏性结膜炎、过敏性皮炎),其中速发型全身不良反应49人次(2.10%),迟发型全身不良反应为30人次(1.29%)。全身不良反应在20~800SQU、2000~80000SQU、100000sqU阶段的发生率分别是:0.35%(2/569)、6.71%(54/805)和2.51%(24/958),差异有统计学意义。结论哮喘患儿对标准化屋尘螨提取液特异性免疫治疗耐受性良好,绝大多数局部不良反应为轻度,其发生率随注射提取物浓度增高而增高。全身不良反应绝大多数为轻度,以发生在2000~80000SQU剂量明显上升阶段为最多,在此阶段多加注意。全身不良反应以注射浓度2000~80000SQU为最高,而局部不良反应以100000SQU组为最高,提示局部不良反应和全身不良反应不平行。局部不良反应发生不提示全身不良反应发生。 Objective To evaluate the safety of specific immunotherapy(SIT) with standardized house dust mite (HDM) vaccine on allergic asthmatic children. Methods 110 patients with mild to moderate asthma who were allergic to PIDM received SIT with a standardized Dermatophagoides pteronyssinus(Der P) extract (Alutard SQ,ALK-Abell6,Denmark). The local side effect and systemic side effect were monitored after each allergen injection. Results All patients completed a total of 2 332 injections. 291 injections (12.48 % ) of all injections caused local side-effects, 79 injections (3.39 % ) have sysmetic side effects. One injections caused severe (non-life-threatening)systemic reactions., symptoms: rapid onset (5 rain after injection) of generalized urticaria, itching, flushing, severe asthma. In different dosage group: 20-800 SQU, 2 000-80 000 SQU, 100 000 SQU, the local side effect and systemic side effect were 1.05%, 12.05%, 19.62% and 0.35% ,6.71% ,2.51%, respectively. Local side effects were not correlated with systemic side effect. Conclusions Complying with the EAACI immunotherapy guidelines, SIT with standardized HDM vaccine is a safe treatment in asthmatic children. A majority of local reactions and all systemic reactions are mild and respond well to ordinary treatment and adjustment of dose-increase schedule.
出处 《国际呼吸杂志》 2008年第23期1413-1416,共4页 International Journal of Respiration
关键词 哮喘 特异性免疫治疗 屋尘螨 Asthma Specific immunotherapy House dust mite
  • 相关文献

参考文献12

  • 1Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Coehrane Database Sys Rev, 2003,4 : CD001186.
  • 2Wang H, Lin X, Hao C, et al. A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy, 2006,61 : 191-197.
  • 3中华医学会儿科学分会呼吸学组.儿童支气管哮喘防治常规(试行)[J].中华儿科杂志,2004,42(2):100-106. 被引量:2631
  • 4向莉,申昆玲,张亚梅,贺建新,张杰,任亦欣,李珍.3~14岁哮喘和变应性鼻炎患儿吸入性致敏原分布特征比较[J].中国实用儿科杂志,2006,21(8):581-583. 被引量:26
  • 5向莉,熊珍谊,任亦欣.哮喘儿童血清变应原特异性IgE分布特征[J].首都医科大学学报,2005,26(5):577-581. 被引量:22
  • 6No authors Listed. Position paper. Immunotherapy. (EAACI) The European Academy of Allergology and Clinical Immunology. Allergy, 1993,48( 14 Suppl ): 7-35.
  • 7Pifferi M, Baldini G immunotherapy with Marrazzini G, et al. Benefits of a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. Allergy, 2002,57 : 785-790.
  • 8Blumberga G,Groes L, Haugaard L, et al. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy, 2006,61 : 843-848.
  • 9Mailing HJ. Minimising the risks of allergen-specific injection immunotherapy. Drug Saf, 2000,23 : 323-332.
  • 10刘光辉,祝戎飞,王忠喜.尘螨变应原疫苗对变态反应性哮喘的脱敏作用[J].医药导报,2004,23(8):543-545. 被引量:11

二级参考文献15

  • 1张宏誉 王良录 等.应用CAP System检测sIgE的评价[J].中华微生物学和免疫学杂志,1996,16(1):6-6.
  • 2Abramson M, Puy R, Weiner J. Allergen immunotherapy for asthma[J]. Cochrane Database Syst Rev, 2003,4:CD001186.
  • 3Humbert M, Grant J A, Taborda-Barata L, et al. High-affinity IgE receptor (FcRI)-bearing cells in bronchial biopsies from atopic and nonatopic subjects[J]. Am J Respir Crit Care Med, 1996,153:1931-1937.
  • 4Host A, Andrae S, Charkin S, et al. Allergy testing in children: Why, Who, When and How? Allergy, 2003,58 : 559 ~ 569
  • 5Pearce N, Pekkanen J, Beasley R. How much asthma is realy attributeable to atopy? Thorax, 1999,54: 268~272
  • 6Wahn U, Mutius E V. Childhood risk factors for atopy and the importance of early intervention. J Allergy Clin Immunol, 2001,107 : 567 ~ 574
  • 7Host A, Halken S, Jacobsen H P, et al. Clinical course of cow's milk protein allergy/intolerance and atopic diseases in childhood. Pediatr Allergy Immunol, 2002, 13(Suppl 15) :23~28
  • 8Spergel J M, Paller A S. Atopic dermatitis and the atopic march. J Allergy Clin Immunol, 2003, 112 (6Suppl): 118 ~ 127
  • 9Sasai K, Furukawa S, Muto T, et al. Early detection of specific IgE antibody against house dust mite in children at risk of allergic disease. J Pediatr, 1996, 128:834 ~ 840
  • 10顾瑞金.变态反应学分册[M].北京:中国协和医科大学出版社,2000.243.

共引文献2673

同被引文献79

引证文献5

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部